Reaction Biology and Key Organics in joint venture

In the joint venture, the companies plan to identify a series of compounds with the potential of becoming new drugs with further research, and then to partner or sell the compounds to pharmaceutical companies interested in the selected targets.

Key will provide compounds for screening against these targets using RBC’s DiscoveryDot screening technology. Key will then provide additional chemical analysis and compound synthesis, and RBC will perform additional screening and profiling. The companies will then collaborate on further development of selected compounds.

US based Reaction Biology provides high throughput screening services to the biotechnology and pharmaceutical industries. The company uses a patent-pending combination of technologies to perform screening at the nanoliter scale.

Key Organics, based in Cornwall, UK, was formed in 1986 to supply schemes of novel, benzenoid and heterocyclic chemistry to its customers under confidentially agreements.